Skip to Content

Roy Fleischmann

Dr. Fleischmann trained in Rheumatology at Columbia Presbyterian Medical Center in NYC and is a Master of the American College of Rheumatology. Dr. Fleischmann is a Clinical Professor of Medicine at the University of Texas Southwestern Medical Center, Co-Medical Director of the Metroplex Clinical Research Center, and co-Director of the Division of Rheumatology at the Presbyterian Medical Center in Dallas.

Roy Fleischmann is an Overseas Fellow of the Royal Society of Medicine, a former President of the Texas Rheumatism Association, and the Dallas–Fort Worth Rheumatism Association, Division Director Rheumatology, St, Paul Medical Center, Dallas. He has been involved in the development of virtually all medications approved for RA, PsA, and SLE in the US and has spoken world-wide on their development and effective use.

Roy Fleischmann has published over 300 peer-reviewed manuscripts and presented over 500 abstracts at major Rheumatology meetings on these topics. He is a strong advocate of Treat-to-Target and the use of jakinibs in RA. He is Editor of Rheumatology and Therapy and on the Editorial Boards of the Annals of Rheumatic Disease, RMD Open and the Journal of Rheumatology and past International Editor of Rheumatology (Oxford). He is a reviewer for the New England Journal of Medicine, The Lancet, Arthritis Rheumatism, Annals of Rheumatic Disease and the Journal of Rheumatology amongst others.

Back to top